Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2/17/26 19:48 | 2/17/26 | AURA | Health | BioPrd | Biological Products, (No Diag | Kilroy Conor | MA | O | See Rema | 2 | S | -100 | 5.21 | 0 | -19 | 179 | D | |||||||||||||||
2/17/26 19:47 | 2/17/26 | AURA | Health | BioPrd | Biological Products, (No Diag | Plavsic Mark | MA | O | CTO | 4 | S | -247 | 6.57 | 0 | -38 | 209 | D | |||||||||||||||
2/17/26 19:47 | 2/17/26 | AURA | Health | BioPrd | Biological Products, (No Diag | Hopkins Janet Jill | MA | O | Chief Me | 4 | S | -326 | 6.29 | 0 | -52 | 270 | D | |||||||||||||||
2/17/26 19:47 | 2/17/26 | AURA | Health | BioPrd | Biological Products, (No Diag | Elazzouzi Amy | MA | O | SVP,Fina | 8 | S.d | -138 | 6.10 | 0 | -23 | 87 | D | |||||||||||||||
2/17/26 19:46 | 2/17/26 | AURA | Health | BioPrd | Biological Products, (No Diag | De Los Pinos Elisabet | MA | DO | See Rema | 7 | S.d | -1,060 | 7.36 | 0 | -144 | 610 | D | |||||||||||||||
5/20/25 17:34 | 5/16/25 | AURA | Health | BioPrd | Biological Products, (No Diag | Gibney Anthony S | MA | O | See Rema | 1 | S.d | -8 | 5.15 | 0 | -2 | 57 | D | |||||||||||||||
10/21/24 18:23 | 10/18/24 | AURA | Health | BioPrd | Biological Products, (No Diag | Feder Julie B | MA | O | CFO | 1 | S.d | -302 | 12.03 | 0 | -25 | 134 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |